Rifampicin-Induced Concomitant Renal Injury and Hepatitis.

Area of Science:

• Nephrology
• Hepatology
• Infectious Diseases

Background:

• Anti-Tubercular Therapy (ATT) is crucial for tuberculosis treatment but can lead to adverse drug reactions.
• Drug-induced hepatitis and renal insufficiency are known complications of ATT, requiring prompt diagnosis.
• Differential diagnoses include viral infections, pre-existing conditions, or drug toxicity.

Observation:

• This case report details a patient experiencing ATT-induced renal failure and hepatitis.
• Rifampicin, a first-line ATT drug, was identified as the suspected causative agent.
• The patient's history included rifampicin re-exposure and alternate-day administration, factors linked to rifampicin-induced renal toxicity.

Findings:

• Rifampicin is associated with various adverse drug reactions, including hepatitis, anemia, and interstitial nephritis.
• Renal toxicity from rifampicin is often observed upon re-exposure or with alternate-day dosing.
• This case underscores the potential for rifampicin to cause both hepatitis and renal failure concurrently.

Implications:

• Prompt identification of drug-induced adverse events is critical for managing tuberculosis patients.
• Suspected drugs, like rifampicin, should be identified to guide treatment adjustments and prevent life-threatening complications.
• Understanding rifampicin's potential for hepatorenal toxicity is vital for optimizing ATT regimens and patient outcomes.